EntryPoint Capital LLC Has $287,000 Stock Position in Accolade, Inc. (NASDAQ:ACCD)

EntryPoint Capital LLC lifted its holdings in Accolade, Inc. (NASDAQ:ACCD) by 128.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,787 shares of the company’s stock after purchasing an additional 47,113 shares during the period. EntryPoint Capital LLC owned 0.10% of Accolade worth $287,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ACCD. Mission Creek Capital Partners Inc. acquired a new stake in shares of Accolade in the third quarter worth about $38,000. Pallas Capital Advisors LLC acquired a new stake in Accolade in the 4th quarter worth approximately $38,000. Wolverine Trading LLC acquired a new stake in Accolade in the 3rd quarter worth approximately $51,000. Point72 Asia Singapore Pte. Ltd. boosted its position in Accolade by 1,144.1% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after purchasing an additional 19,232 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Accolade during the third quarter valued at approximately $96,000. 84.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ACCD has been the subject of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Stifel Nicolaus restated a “hold” rating and set a $7.03 price target (down from $8.00) on shares of Accolade in a report on Thursday, January 9th. Stephens reiterated an “equal weight” rating and issued a $7.03 price objective on shares of Accolade in a research note on Wednesday, February 12th. Leerink Partners restated a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Finally, William Blair downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Thirteen research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.51.

Accolade Trading Up 0.1 %

Shares of ACCD stock opened at $7.00 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The firm has a fifty day moving average of $6.93 and a 200-day moving average of $4.93. Accolade, Inc. has a 52-week low of $3.08 and a 52-week high of $10.68. The stock has a market cap of $573.95 million, a price-to-earnings ratio of -3.11 and a beta of 2.18.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities research analysts forecast that Accolade, Inc. will post -1.2 earnings per share for the current fiscal year.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.